Deployment of artificial intelligence for point-of-care clinical decision support is in its nascency. Despite the media attention and proliferation of AI studies, translation to clinical practice is ...

Healthcare’s AI story is changing. For several years, generative AI largely lived in the “pilot era,” marked by experimentation, point solutions and cautious optimism. In 2026, that era is giving way ...

The recently released rules for developing an accountable care organization are designed to reach the Triple Aim: improved experience of care, improved health of populations and reduced costs. While ...

The clinical decision support space within the broader healthcare AI market is getting more and more crowded, with startups spawning a plethora of tools that help clinicians complete a variety of ...

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study The IPSS-M provides important new ...

Please provide your email address to receive an email when new articles are posted on . The intervention reduced patients’ mean systolic BP by 14.6 mm HG. However, there was no difference between the ...

Please provide your email address to receive an email when new articles are posted on . Patients on the clinical decision support system had greater systolic blood pressure change. Mean systolic blood ...

Dr. Eve Cunningham is group vice president and chief of virtual care and digital health at health system Providence and founder of MedPearl. And Providence is getting ready to spin off MedPearl.

The emergence of large language models (LLMs) prompted one research team to compare how well this technology performs compared with traditional clinical decision support systems in identifying ...

A computerized clinical decision support system for primary care physicians led to meaningful systolic blood pressure decline in patients with CKD and uncontrolled hypertension. Implementing a ...

STONY BROOK, NY / ACCESSWIRE / June 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a global leader in PCR-based DNA technologies, today announced that its molecular diagnostics ...